Synthetically engineered bacteria destroys superbugs

By Admin
Share
Scientists in Singapore have engineered a ‘suicide bomber strain of bacteria which has the ability to destroy a common but deadly hospital superb...

Scientists in Singapore have engineered a ‘suicide bomber’ strain of bacteria which has the ability to destroy a common but deadly hospital superbug.

The researchers have taken a strain of E.Coli which is commonly present in the human gut and empowered it to recognise and kill the Pseudomonas aeruginosa bacteria.

Upon recognising the superbug the newly engineered bacteria produces a fatal toxin, before exploding to cover the entire area in the chemical.   

It is thought this is the first time a study has used synthetic biology to tackle an infectious diseases.

READ MORE FROM THE WDM CONTENT NETWORK:

To read the latest edition of Healthcare Global, click here

Lab tests of the bacteria found it destroyed 99 percent of targets and it is now hoped it could be used to tackle drug-resistant superbugs and infections.  

Pseudomonas aeruginosa is often found in hospitals and targets patients with weakened immune systems.

The superbug can be fatal as it causes infections in any bodily tissues that it can attach itself too, including the lungs, guts and the bladder.

The results of the research have been published in the Molecular Systems Biology journal.

Share

Featured Articles

NTT & Olympus: World's First Cloud Endoscopy System

NTT and medical technology company Olympus put on a demonstration, showing the IOWN APN's low-latency capability, for the first cloud endoscopy system

Richter BioLogics' New Biopharmaceutical GMP Facility

Richter BioLogics GmbH & Co KG's a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment

GE HealthCare's Pilot Study Shows Value of Portrait Mobile

A pilot study from GE Healthcare has shown the value of Portrait Mobile Continuous Monitoring Solution, a leap in post-surgical monitoring efficiency

50% of Teens to be Affected by Myopia Globally by 2050

Telehealth & COVID-19

NVIDIA’s AI Insights for Diabetes Prevention with GluFormer

Technology & AI

Novo Nordisk's CagriSema Next Gen Weight-Loss Treatment

Medical Devices & Pharma